Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

Chih-Jen Yang; Yu-Jui Wei; Hsu-Liang Chang; Pi-Yu Chang; Chung-Chen Tsai; Yen-Hsu Chen; Po-Ren Hsueh

Journal of Microbiology, Immunology and Infection (Feb 2021)

Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

Chih-Jen Yang,
Yu-Jui Wei,
Hsu-Liang Chang,
Pi-Yu Chang,
Chung-Chen Tsai,
Yen-Hsu Chen,
Po-Ren Hsueh

Affiliations

Chih-Jen Yang: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Yu-Jui Wei: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Hsu-Liang Chang: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Pi-Yu Chang: Department of Management, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Chung-Chen Tsai: Department of Medical Information of Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Yen-Hsu Chen: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan; Corresponding author. Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, No. 100, Tzyou First Road, Kaohsiung City, Taiwan. Fax: +886 7 316 1210.
Po-Ren Hsueh: Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Corresponding author. Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung Shan South Road, Taipei, 100, Taiwan.

Journal volume & issue: Vol. 54, no. 1
pp. 27 – 36

Abstract

Read online

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).

Published in Journal of Microbiology, Immunology and Infection

ISSN: 1684-1182 (Print)
Publisher: Elsevier
Country of publisher: Hong Kong
LCC subjects: Science: Microbiology
Website: https://www.sciencedirect.com/journal/journal-of-microbiology-immunology-and-infection

About the journal

Abstract

Keywords